Meghan Scanlon's most recent trade in Paragon 28 Inc was a trade of 15,906 Common Stock done . Disclosure was reported to the exchange on May 17, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Paragon 28 Inc | Meghan Scanlon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2024 | 15,906 | 42,113 | - | 0 | Common Stock | |
| Paragon 28 Inc | Meghan Scanlon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 8,361 | 26,207 | - | 0 | Common Stock | |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2022 | 2,062 | 25,067 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2022 | 2,062 | 2,062 | - | - | Deferred Stock Units | |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.11 per share. | 01 May 2022 | 606 | 24,461 (0%) | 0% | 42.1 | 25,519 | Common Stock |
| Paragon 28 Inc | Meghan Scanlon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 17,846 | 17,846 | - | 0 | Common Stock | |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 1,019 | 0 | - | - | Deferred Stock Units | |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 1,019 | 23,305 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.17 per share. | 28 Feb 2022 | 300 | 23,005 (0%) | 0% | 44.2 | 13,251 | Common Stock |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 8,283 | 8,283 | - | - | Performance Share Units | |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2022 | 779 | 779 | - | - | Deferred Stock Units | |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2022 | 779 | 22,515 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.55 per share. | 21 Feb 2022 | 229 | 22,286 (0%) | 0% | 42.6 | 9,744 | Common Stock |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2022 | 1,583 | 4,750 | - | - | Restricted Stock Units | |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2022 | 1,583 | 21,445 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2022 | 1,112 | 2,224 | - | - | Deferred Stock Units | |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2022 | 1,112 | 22,063 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.83 per share. | 17 Feb 2022 | 494 | 20,951 (0%) | 0% | 42.8 | 21,158 | Common Stock |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.55 per share. | 17 Feb 2022 | 327 | 21,736 (0%) | 0% | 42.6 | 13,914 | Common Stock |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 24,264 | 24,264 | - | - | Stock Option (Right to Buy) | |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 8,486 | 8,486 | - | - | Restricted Stock Units | |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2022 | 1,108 | 20,250 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2022 | 1,108 | 1,108 | - | - | Deferred Stock Units | |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.01 per share. | 15 Feb 2022 | 388 | 19,862 (0%) | 0% | 44.0 | 17,076 | Common Stock |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 15,257 | 15,257 | - | - | Restricted Stock Units | |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jul 2021 | 13,850 | 0 | - | - | Stock Option (Right to Buy) | |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.41 per share. | 27 Jul 2021 | 13,850 | 32,992 (0%) | 0% | 23.4 | 324,229 | Common Stock |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Sale of securities on an exchange or to another person at price $ 45.01 per share. | 27 Jul 2021 | 13,850 | 19,142 (0%) | 0% | 45.0 | 623,389 | Common Stock |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2021 | 855 | 0 | - | - | Deferred Stock Units | |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2021 | 855 | 18,685 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.36 per share. | 01 Jul 2021 | 251 | 18,434 (0%) | 0% | 43.4 | 10,883 | Common Stock |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Sale of securities on an exchange or to another person at price $ 44.03 per share. | 24 Jun 2021 | 16,450 | 17,830 (0%) | 0% | 44.0 | 724,294 | Common Stock |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2021 | 16,450 | 0 | - | - | Stock Option (Right to Buy) | |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.26 per share. | 24 Jun 2021 | 16,450 | 34,280 (0%) | 0% | 17.3 | 283,927 | Common Stock |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2021 | 2,061 | 4,124 | - | - | Deferred Stock Units | |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2021 | 2,061 | 18,435 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.60 per share. | 01 May 2021 | 605 | 17,830 (0%) | 0% | 43.6 | 26,378 | Common Stock |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 1,018 | 16,673 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 1,018 | 1,019 | - | - | Deferred Stock Units | |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.78 per share. | 28 Feb 2021 | 299 | 16,374 (0%) | 0% | 38.8 | 11,595 | Common Stock |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2021 | 3,940 | 3,940 | - | - | Performance Share Units | |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2021 | 1,159 | 0 | - | - | Deferred Stock Units | |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2021 | 1,159 | 15,993 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2021 | 779 | 1,558 | - | - | Deferred Stock Units | |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2021 | 779 | 15,057 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Payment of exercise price or tax liability using portion of securities received from the company at price $ 39.20 per share. | 21 Feb 2021 | 338 | 15,655 (0%) | 0% | 39.2 | 13,250 | Common Stock |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.03 per share. | 21 Feb 2021 | 223 | 14,834 (0%) | 0% | 38.0 | 8,481 | Common Stock |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 20,368 | 20,368 | - | - | Stock Option (Right to Buy) | |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 6,333 | 6,333 | - | - | Restricted Stock Units | |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2021 | 1,111 | 3,336 | - | - | Deferred Stock Units | |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2021 | 1,111 | 14,650 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Payment of exercise price or tax liability using portion of securities received from the company at price $ 37.52 per share. | 17 Feb 2021 | 372 | 14,278 (0%) | 0% | 37.5 | 13,957 | Common Stock |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2021 | 1,107 | 2,216 | - | - | Deferred Stock Units | |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2021 | 1,107 | 13,927 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Meghan Scanlon | SVP,Pres,Urology Pelvic Health | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.39 per share. | 15 Feb 2021 | 388 | 13,539 (0%) | 0% | 38.4 | 14,895 | Common Stock |